Medical Devices & Technology

SHERIDAN, WYOMING – May 19, 2025 – Royal Philips has announced the European launch of its VeriSight Pro 3D Intracardiac Echocardiography (ICE) catheter, marking a significant step in transforming structural heart procedures through minimally invasive, real-time imaging technology. Already established in the U.S. market, this cutting-edge device supports more efficient, patient-friendly interventions without requiring general anesthesia — a major development for healthcare providers facing rising demands in structural heart disease care.

Revolutionizing Intracardiac Imaging and Clinical Workflows

VeriSight Pro introduces a miniaturized ultrasound probe at the tip of a steerable catheter, just 3 millimeters in diameter, enabling detailed 2D and 3D imaging directly inside the heart. This innovation allows physicians to perform complex interventions with increased confidence, streamlined workflows, and reduced procedural burden.

SHERIDAN, WYOMING – May 19, 2025 – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, has announced the successful pricing of a €1 billion dual-tranche bond issuance under its European Medium Term Note (EMTN) program, marking a strategic step to reinforce its capital structure and advance sustainable investment goals.

The offering consists of €500 million in fixed-rate notes due 2030 and another €500 million in notes due 2035. This financial move is designed to refinance existing 2026 debt maturities and fund eligible green projects as defined in the company’s Sustainable Finance Framework. With significant investor interest, both tranches were heavily oversubscribed—by more than three times for the 2030 notes and more than four times for the 2035 notes—underscoring strong market confidence in Philips’ long-term strategy and ESG commitments.

Strategic Financial Optimization with ESG Integration

SHERIDAN, WYOMING – May 17, 2025 – Danaher Corporation is reinforcing its position at the forefront of life sciences and diagnostics innovation through its Beacon program—an initiative designed to transform cutting-edge academic research into scalable, market-ready solutions. Spearheaded by Vanessa Almendro, PhD, MBA, Vice President, Head of Science and Technology Innovation at Danaher, the Beacon model exemplifies how strategic academic-industry collaboration can generate high-impact innovations aligned with real-world healthcare and biotechnology challenges.

A Structured Pathway from Discovery to Deployment

SHERIDAN, WYOMING – May 9, 2025 – LivaNova PLC, a global leader in medical technology, announced strong first-quarter 2025 results today, demonstrating continued growth and operational efficiency. The company reported high single-digit revenue growth, including double-digit organic revenue increases, as well as expanding operating margins. LivaNova also raised its full-year 2025 revenue guidance, taking into account the impact of the SNIA environmental liability and current tariffs.

Strong Financial Performance in Q1 2025

For the first quarter of 2025, LivaNova recorded total revenue of $316.9 million, a 7.4% increase compared to the same period in 2024. On a constant-currency basis, revenue grew by 8.9%, with organic revenue expanding by 10.4%. Key drivers of growth included strong demand in the Cardiopulmonary and Neuromodulation segments, as well as increased sales from the Essenz™ Perfusion System and cardiopulmonary consumables.

SHERIDAN, WYOMING – May 9, 2025 – LivaNova PLC, a leading global medical technology company, has announced 12-month top-line data from its OSPREY clinical trial. The study demonstrates promising results for the aura6000™ System, an investigational device designed to treat moderate to severe obstructive sleep apnea (OSA). The data highlights sustained improvements in key health metrics, positioning the aura6000™ as a potential breakthrough in OSA management.

Strong Results from 12-month OSPREY Data

The OSPREY trial's 12-month data shows significant improvements for patients receiving the aura6000™ System, demonstrating the effectiveness of proximal hypoglossal nerve stimulation (p-HGNS) in managing OSA. The results confirm the system’s potential as a long-term solution for patients with moderate to severe cases who have previously struggled with conventional treatments.

Key highlights from the study include:

SHERIDAN, WYOMING – May 09, 2025 – Globus Medical, Inc. (NYSE: GMED), a leading provider of musculoskeletal solutions, has announced its financial results for the first quarter of 2025. The company reported worldwide net sales of $598.1 million, reflecting a 1.4% decrease year-over-year, primarily driven by a slowdown in Enabling Technology deal closures and temporary supply chain disruptions. Despite these challenges, Globus Medical saw notable growth in its core U.S. spine business and remains optimistic about its future prospects.

SHERIDAN, WYOMING – May 9, 2025 – Globus Medical, Inc. (NYSE: GMED), a prominent player in the musculoskeletal solutions industry, has reported its financial results for the first quarter of 2025. Despite a slight dip in global net sales, the company remains confident in its ability to drive long-term growth and innovation. The results reflect challenges faced in certain areas, including slower deal closures in Enabling Technology, but also showcase the company’s strong positioning in the U.S. spine business.

SHERIDAN, WYOMING – May 9, 2025 – Enovis Corporation (NYSE: ENOV), a global leader in medical technology, has appointed Damien McDonald as its new Chief Executive Officer, effective May 12, 2025. McDonald, who will also join the Enovis Board of Directors following the Company’s 2025 Annual Meeting of Stockholders, succeeds Matt Trerotola, who has announced his retirement. This strategic leadership transition positions Enovis for continued growth and innovation in the medical technology sector.

SHERIDAN, WYOMING – May 8, 2025 – Invacare is proud to announce the launch of its global fundraiser, Move For Mobility 2025, which aims to provide life-changing wheelchairs to individuals in need around the world. The initiative brings together Invacare employees, ambassadors, clients, and partners in a worldwide effort to raise awareness and funds for the Free Wheelchair Mission, an organization committed to delivering wheelchairs at no cost to people with disabilities in remote communities.

A Strong Partnership with Free Wheelchair Mission

Since its inception, Invacare has partnered with Free Wheelchair Mission, a humanitarian non-profit organization, to help deliver mobility solutions to underserved populations globally. This year marks the sixth year of this partnership, with Invacare contributing its engineering, testing, and distribution expertise to help create durable and effective wheelchairs.

SHERIDAN, WYOMING – May 8, 2025 – B. Braun Group has demonstrated resilience and strategic growth amidst challenging global conditions, reporting a 4.4% increase in sales for the 2024 fiscal year. The company’s focus on innovation, operational efficiency, and modern technology investments has contributed to a solid financial performance, reaffirming its commitment to advancing healthcare solutions worldwide.

Robust Financial Growth and Increased Efficiency

In a year marked by rising costs and market volatility, B. Braun’s fiscal year 2024 results showcase the company’s ability to drive growth and improve profitability. The company’s sales surged to 9.1 billion euros, up from 8.8 billion euros the previous year. At constant exchange rates, this represents a notable 6.8% increase, aligning with B. Braun’s long-term growth target of 5-7%.

Key highlights from the 2024 fiscal year include: